Technical Data
A2300-04
Aprotinin, Bovine (US/North America) (Pancreatic trypsin inhibitor)
250mg
|
Technical Data |
|
A2300-04 |
Aprotinin, Bovine (US/North America) (Pancreatic trypsin inhibitor) |
250mg |
| Molecular Biology | Storage: -20°CShipping: RT |
|
Aprotinin inhibits the activity of several proteolytic enzymes such as chymotrypsin, kallikrein, plasmin and trypsin. It is present in blood and in most tissues, with a high concentration in lung, inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins. Aprotinin is a natural proteinase inhibitor polypeptide consisting of 58 amino acids arranged in a single polypeptide chain, cross-linked by three disulfide bridges and having a molecular mass of 6512D. Solubility: Colorless, clear, complete Loss on drying: 2.0% Absorbance: 0.8 Histamine: 0.2ug/3EU Activity (on dried basis): 5400KIU/mg Protein impurities of higher molecular mass: Complies Bacterial endotooxins: None Detected Abnormal toxicity: Non-toxic Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with ddH2O. Aliquot and store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. CAS Number: 9087-70-1 |
Source: Bovine lung Form: Supplied as a white powder. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Alston, T.A.: Aprotinin. Int. Anesthesiol. Clin. 42(4): 81-91 (2004). 2. Apeler, H., Peters, J., Schneider, K.H., Dembowsky, K.: Expression, purification, biochemical and pharmacological characterization of a recombinant aprotinin variant. Arzneimittelforschung 54(8): 483-97 (2004). 3. Khan T.A., Bianchi, C., Feng, J., Stahl, G.: Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J. Thorac. Cardiovasc. Surg. 128(4): 602-8 (2004). 4. Gillespie, E.L., Perkerson, K.A., Coleman, C.I.: Possible impact of aprotinin on post-cardiothoracic surgery atrial fibrillation. Conn. Med. 68(7): 439-42 (2004). 5. Levy, J.H.: Safety of aprotinin in heparinized and nonheparinized patients. J. Cardiothorac. Vasc. Anesth. 18(4 Suppl): 38S-42S (2004). 6. Porte, R.J., Hendriks, H.G.: Blood conservation in liver transplantation: The role of aprotinin. J. Cardiothorac. Vasc. Anesth. 18(4 Suppl): 31S-37S (2004).
|
||